CN

CN EN

 

Newsroom

Company News

Home > Newsroom > Company News Print
11/10/2019
CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership
  •            The new partnership will combine theresearch and development ingenuity of BJ Bioscience with the state-of-art biologicsmanufacturing set up of CMAB

  • CMAB will provide full development andmanufacturing services for BJ Bioscience’s BJ-005 bi-functional antibody

  • BJ-005 is planned to enter clinicalstudies in China and the US following a dual IND filing

Suzhou/Hangzhou, China, October 11th,2019 - CMAB Biopharma (Suzhou) Inc. (“CMAB”), a pure-play biologics CDMO and BJ Bioscience Inc. (“BJ Bioscience”), an innovative biopharmaceutical enterprise, today announced a comprehensive strategic agreement for thedevelopment and manufacturing of a Bi-functional Antibody (BJ-005) as the first step in an exclusive collaboration.

Under this agreement, CMAB will provide a full range of CMC research and manufacturing services that meet the IND application requirements of both China and the United States. The strategic cooperation will support the clinical development of BJ-005 worldwide by BJ Bioscience and is based upon CMAB's award-winning CMC process development and manufacturing platform, an experienced R&D team in IND applications in both China and the United States, and an impeccable product quality system.

“We had ambitiousgoals and aspirations at the beginning of setting up BJ Bioscience,” said Mr. Xiaoyong, JIN, Chairman of BJBioscience. “So far, China’s biopharmaceutical companies have very few innovative drugs on the market. We believe that BJ Bioscience will develop real innovative biologics in the foreseeable future. This is a high-risk, considerably complexsystematic project. To achieve such objective, I have started system icpreparation for the entire innovation chain, from deep gene sequencing and datamining to large animal transgenic models for validation of function of new genes.Only through such wholistic efforts can we discover new targets and develop brand-new large and small molecular drugs as well as gene therapy products around thesenew targets. All the companies along the innovation chains are BJ Bioscience’s sistercompanies. The cluster of companies on this ecological chain will produce synergy.The primary goal for our cooperation with CMAB is that we may focus more on theinnovative R&D fields that we are good at and leave the CMC part to CMABbecause it is its expertise. We believe that our efforts in all respects willopen up an era for stronger, win-win cooperation.”

“CMAB stood out inour strict screening of a number of CDMO companies for many reasons. First of all, BJ Bioscience and CMAB share the same view on talents. We both think that talent prevails over everything. In recent years, BJ Bioscience has attracted many outstanding returnees and talents with both academic and biopharmaceutical industry experience. We highly appreciate CMAB for that it has done exactly the same over the years. CMAB boasts a competent CMC research and manufacturingteam covering the entire chain of CMC. Secondly, BJ Bioscience does not develop ME TOO products. We strive to make breakthroughs and innovations. BJ Bioscienceis strong in discovery and development of innovative biologics and, therefore, weneed a strong CMC partner with a strong expertise and experience in compliancelike CMAB. Last but not least, CMAB, as a pure-play CDMO company, advocates absolute protection of the intellectual property rights of its customers.Therefore, we believe that our cooperation will accelerate the R & D process of BJ-005. We hope that such collaboration will speed up the development of the innovative therapies of BJ Bioscience to the patients worldwide,” said Dr. Haizhou ZHANG, Co-founder and CEO of BJBioscience.

“We are extraordinarily delighted and honored to have the opportunity to provide CMC research and manufacturingservices to cutting-edge biomedical R&D companies like BJ. CMAB fully understands the most critical needs of innovative drug R&D startups such as BJ. Our objective is to support BJ in attaining another milestone through thequality of IND applications in both China and the United States at the highest speed possible. CMAB will achieve this through our excellent core team, which has practical experience in IND applications in both regions, a maturetechnology integration capability, pure CDMO services, equipment and facilitiesof international mainstream brands, and a first-class international GMP qualitysystem (as demonstrated by recent success in an external European QP audit).CMAB has won the trust of an increasing number of young innovative R&D institutions like BJ, which has enabled us to develop our dedication to doing every project well and serving every customer well,” said Dr. Yongzhong WANG, CMAB CEO.

About BJ Bioscience

BJ BioscienceInc. is a biotechnology company dedicated to the research and development ofinnovative drugs. It is created by returnees with many years of experience inresearch and development of innovative drugs and complimentary expertise,including a review expert of National Key Innovative Drug R&D Projects, theNational Health Commission of China. Based on its top notch trade secretprotected antibody generation and screening technology, BJ Bioscience focusesits R&D in cancer, infectious and autoimmune diseases. Key members of thecompany's R&D team have many years of experience in research anddevelopment and management of antibody drugs from key national scientificresearch institutions, domestic and multinational pharmaceutical companiesespecially European and American multinational companies. It has developed andenjoys the global patent of the world’s first tumor-targeting IL-15 fusionprotein (BJ-001), which had been approved by FDA of the United States.

To find out moreplease visit www.en.bjbioscience.com

BJ BioscienceInc.

Tel: (+86)0571-89188996

Email: bjbio@bjbioscience.com

Address: 15thFloor, Building 4, Health Valley, 1500 Wenyi West Road, Yuhang District,Hangzhou

About CMAB Biopharma Inc.

CMAB BiopharmaInc. is a flexible full-service CDMO dedicated to providing bespoke developmentand manufacturing services of antibodies and biologics for clients in China andacross the globe. Our adaptable, service-oriented business enables clients totake their innovative concepts for tomorrow's medicines from DNA to clinicalproduct today.

To find out moreabout our fully integrated CDMO, please visit wwwNaNabbio.com/en

Or contact us:

CMAB Biopharma(Suzhou) Inc.

Tel: (+86) 051267995188

Email:hello@cmabbio.com

Address:Building C37, No. 188 Dong Ping Road, Suzhou Industrial Park, China 215123


Follow us

Site Map|Privacy Policy|Terms of Use|Contact

Copyright © 2018 CMAB BioPharma (Suzhou) Inc.   苏ICP备18005502号